AMERICAN SOCIETY OF CLINICAL ONCOLOGY

U.S. Surgeon General Dr. Vivek Murthy highlights alcohol as a significant cancer risk, linking even minimal daily consumption to increased risks of seven cancer types. Alcohol is the third leading preventable cause of cancer in the U.S., with 20,000 alcohol-related cancer deaths annually. Murthy advocates for revised dietary guidelines and warning labels on alcoholic beverages to raise public awareness.

Innovent Biologics announced China's NMPA approved DOVBLERON® for ROS1-positive NSCLC, based on TRUST-I trial results showing high efficacy. DOVBLERON® is Innovent's 13th product, offering a new treatment option for lung cancer patients. Innovent aims to enhance patient care with innovative medicines.

Innovent Biologics announced China's NMPA approved DOVBLERON® for ROS1-positive NSCLC, based on TRUST-I trial results showing high efficacy and safety. DOVBLERON® offers a new treatment option for lung cancer patients.

Dana-Farber Cancer Institute research identifies rare germline genetic abnormalities increasing childhood cancer risk, suggesting potential for improved treatments and screening. Findings highlight structural gene variants' role in pediatric cancers, with implications for future diagnostics and targeted therapies.

Innovent Biologics received NMPA approval for DOVBLERON, a taletrectinib adipate capsule, for treating ROS1-positive NSCLC. This marks Innovent’s 13th commercial product, enhancing its TKI franchise to benefit lung cancer patients. Approval followed positive Phase 2 TRUST-I trial results, with a second NDA for untreated patients under Priority Review.

Lynn M. Schuchter, MD, influenced by mentors like John H. Glick, MD, has dedicated her career to melanoma research and patient care at Penn Medicine. Her work includes groundbreaking clinical trials and leadership roles, emphasizing compassion and collaboration in oncology.

A groundbreaking MSK trial achieved 100% remission in rectal cancer patients using dostarlimab, an immunotherapy, bypassing traditional treatments' side effects. This marks a paradigm shift in oncology, preserving patients' quality of life.

GSK's GSK5764227 (GSK’227), a B7-H3-targeted antibody-drug conjugate, received FDA Breakthrough Therapy Designation for treating relapsed or refractory osteosarcoma, a rare bone cancer with no approved treatments post two prior therapies. This designation aims to expedite development, supported by ARTEMIS-002 study data, highlighting GSK’227's potential in addressing unmet medical needs in difficult-to-treat cancers.

Can-Fite BioPharma to present Namodenoson's liver-protective effects at the 2025 ASCO Gastrointestinal Cancers Symposium. Namodenoson, in Phase III for advanced liver cancer, uniquely combines anti-cancer and liver-protective properties, mediated via adiponectin.

Can-Fite BioPharma to present Namodenoson's liver protective effect at the 2025 ASCO Gastrointestinal Cancers Symposium. Namodenoson, in Phase III for advanced liver cancer, uniquely combines anti-cancer and liver-protective effects, mediated via adiponectin.